PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2360469-3	1990	9L cells indicative of a low O6-MT activity showed 13 microM for ACNU and 18 microM for MCNU at a 10% survival dose (SD10), determined by a clonogenic cell assay as an index of cellular resistance.	Nimustine	65-69	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-3	1990	9L cells indicative of a low O6-MT activity showed 13 microM for ACNU and 18 microM for MCNU at a 10% survival dose (SD10), determined by a clonogenic cell assay as an index of cellular resistance.	ranimustine	88-92	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Nimustine	91-95	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	ranimustine	100-104	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Bleomycin	167-176	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Bleomycin	178-181	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Zinostatin	184-200	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Zinostatin	202-205	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Cisplatin	208-236	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Cisplatin	243-247	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Etoposide	254-263	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34	
2360469-7	1990	This correlation between the O6-MT activity and the cellular resistance to nitrosoureas as ACNU and MCNU was not observed among other antitumour drugs, which included bleomycin (BLM), neocarzinostatin (NCS), cis-diamminedichloroplatinum (II) (CDDP), and etoposide (VP-16) in clinical use for brain tumour chemotherapy.	Etoposide	265-270	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	29-34